Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

Nanjing Leads Biolabs (9887.HK) announced it has filed a biologics license application (BLA) for Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy for treatment. The news is a positive regulatory milestone but provides no efficacy/safety data or approval timing in the excerpt, so near-term market impact is likely limited.

Analysis

Nanjing Leads Biolabs (9887.HK) announced it has filed a biologics license application (BLA) for Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy for treatment. The news is a positive regulatory milestone but provides no efficacy/safety data or approval timing in the excerpt, so near-term market impact is likely limited.